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ABSTRACT 
Resection of malignant tumors in the lung represents greater than 70% of thoracic 
surgeries. The continuous evolution of new surgical techniques and management of 
malignant diseases have improved the clinical outcomes of survival and quality of life. 
The aim of this thesis is to review important clinical aspects of the surgical resection 
of malignant tumors in the lung. 
Study I A prospective population-based cohort assessment of the relation between 
preoperative baseline self-reported SF-36 questionnaire data and long-term survival 
after thoracic procedures. The study included 249 patients planned for thoracic 
surgery at Karolinska University Hospital, Stockholm, Sweden, between 2006 and 
2008. During an 8.0-year (median) follow-up, 48% of patients died. Patients with a 
physical component summary score less than the reference experienced significantly 
higher mortality rates compared with those of patients with lower mental component 
summary scores (hazard ratio [HR], 2.02; 95% confidence interval [CI], 1.34–3.06, p 
= 0.001) and (HR, 1.32; 95% CI, 0.84–3.06, p = 0.233), respectively. 
Study II A population-based cohort study of 184 patients who underwent pulmonary 
metastasectomy for colorectal cancer at Karolinska University Hospital between 
January 1, 2004, and December 31, 2015. The median follow-up was 3.2 years, and 
36% (66/184) of patients died. Five-year overall survival was 60% (95% CI, 50%–
68%), and carcinoembryonic antigen levels were the only statistically significant 
prognostic factor of mortality (age- and sex-adjusted, [HR, 2.46; 95% CI, 1.15–5.26, 
p = 0.020]). 
Study III A nationwide cohort study to investigate overall survival after surgical 
resection of pulmonary metastases of colorectal cancer in Sweden and to assess the 
discriminatory power of a recently suggested risk-prediction model. This study, which 
used the Swedish national quality register for thoracic surgery (ThoR), included 756 
patients who underwent surgery between 2009 and 2015. Five-year overall survival 
was 56%, and the median follow-up was 2.9 years. 
Study IV Evaluation of early and late clinical outcomes after video-assisted thoracic 
surgery (VATS) and thoracotomy-lobectomy for non-small cell lung cancer of a cohort 
of patients in Sweden. The study used the ThoR register and included patients (n = 
285) who underwent VATS lobectomy at Karolinska University Hospital and patients 
(n = 1316) who underwent thoracotomy lobectomy at other hospitals in Sweden 
between 2012 and 2015. 
Study V A study of a nationwide cohort conducted in Sweden to determine if the 
weekday of surgery influenced the long-term survival of patients listed in the ThoR 
register who underwent surgery for lung cancer between 2009 and 2015. 
 
Conclusions 
Study I - Preoperative self-reported physical quality of life lower than the reference 
value was significantly related to poor long-term survival after thoracic surgery. 
Study II - Long-term survival after pulmonary metastasectomy for colorectal cancer 
(CRC) at Karolinska University Hospital was comparable with the previously reported 
higher levels, and the number of surgeries increased during the study period. 
Prethoracotomy carcinoembryonic antigen concentrations ≥4 ng/mL were the only 
significant prognostic factor for survival. 
Study III - In Sweden, long-term survival after pulmonary metastasectomy for CRC 
was consistent with better survival reported by contemporaneous studies. External 
validation of a recently proposed risk prediction model achieved good discrimination 
among Swedish patients. 
Study IV - VATS lobectomy achieved better short- and long-term outcomes compared 
with thoracotomy, indicating the feasibility and safety of the VATS technique for 
treating patients with early NSCLC. 
Study V - There was no significant difference between all-cause mortality and the 
weekday of surgery of patients with lung cancer in Sweden. 
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1 INTRODUCTION 
 
General thoracic surgery (GTS) encompasses a wide range of surgical treatments in 
the disciplines of oncology, infectious diseases, trauma, and plastic surgery of the 
chest wall. Surgical resection of malignant tumors in the lung (primary lung cancer 
and metastases from other cancers) represents approximately 70% of GTS 
procedures.1, 2 
The use of GTS for treating cancer has increased during the last three decades. 
Continuous innovations and advances in the diagnosis and treatment of cancer, 
together with a dynamic patient population, partially explain this increase.3, 4 
Pulmonary metastasectomy of metastatic cancers has become an essential part of 
multimodal treatment of metastatic cancers such as metastatic colorectal cancer 
(CRC). The continuous improvements in the management of CRC accompanied by 
the development of minimally invasive GTS provides many patients with the 
opportunity to undergo surgery, which was previously contraindicated because of a 
patient’s poor general condition or multiple recurrences of the disease.5 Despite the 
increasing trend in surgical resection of pulmonary metastases of patients with CRC, 
we are unaware of strong evidence supporting the conclusion that survival has 
improved.4 
Video-assisted thoracic surgery (VATS) lobectomy, introduced during the last three 
decades, serves as an alternative to conventional thoracotomy in the surgical 
management of early-stage non-small cell lung cancer (NSCLC). The technique has 
attracted considerable interest worldwide, with increasing evidence supporting its 
feasibility and ability to improve clinical short-term outcomes compared with those of 
thoracotomy.6 In Sweden, VATS lobectomy was introduced in 2012, and according to 
the records of the Swedish national quality register for thoracic surgery (ThoR),7 
nearly all procedures performed in the subsequent 4 years were performed at one of 
eight thoracic centers. 
Health-related quality of life (HRQOL) is an important aspect of the health care, 
particularly for patients with malignant diseases. Recently, the use of self-reported 
QOL to help make clinical decisions has increased attention on this characteristic to 
complement other objective health measures.8-10 
The aim of this thesis was to investigate several important clinical aspects of the 
surgical resection of malignant tumors in the lung, with emphasis on prognostic 
factors, surgical outcomes, and surgical techniques. 
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2 BACKGROUND 
2.1 LUNG CANCER 
The incidence and death rates of lung cancer worldwide are the highest among 
cancers. Approximately 1.8 million new cases and 1.6 million deaths were recorded 
worldwide in 2012, corresponding to 12.9% of new cancers and 19.4% of cancer 
deaths. Notably, lung cancer accounts for more deaths of men and women than other 
cancers.11 
In Sweden, lung cancer is the fifth most common cancer, although it is the leading 
cancer-related cause of death. The disease has increased among women since the 
1980s, while decreasing among men. This may reflect the change in women’s 
smoking habits since the 1960s. In 2011, 3652 new cases of lung cancer were 
registered, 1869 in men and 1783 in women.12 
Despite recent developments in cancer treatment, lung cancer survival has only 
marginally improved in recent decades, and 5-year survival is approximately 16%. 
Surgery is the best curative treatment for resectable and operable early-stage (I and 
II) NSCLC, achieving 5-year survival rates of 60%–80% for stage I and 30%–50% for 
stage II.13 
2.2 THOR 
ThoR includes records for all thoracic procedures except cardiac and great vessel 
surgery. The registry, which is accessed via the Internet, collects data from the eight 
thoracic centers in Sweden. Reporting from each center is continuous via a special 
login to the website. This service gathers relevant information before, during, and 
after surgery about patients’ risk profiles, medical-technical treatments, outcomes, 
and possible surgical complications. Comparisons can be made among hospitals and 
regions. Survival data are continuously updated from the Total Population Register 
(Statistics Sweden).7 
When ThoR was initiated in 2008, the participation rates were low, subsequently 
increasing to approximately 50% of centers between 2009 and 2011. Complete 
coverage of all eight thoracic centers was achieved in 2013 (see table below). 
  
 4 
 
Number of operations per clinic year 2008-2015 
(Adapted from ThoR Annual Report 2015, available at http://www.ucr.uu.se/thor) 
 
2.3 SHORT FORM 36 (SF-36) HRQOL QUESTIONNAIRE 
SF-36 is a validated generic QOL instrument, which is available in various languages 
and includes reference values from the general population. The instrument evaluates 
eight dimensions of health as follows: physical function, role limitations caused by 
physical problems, pain, vitality, perception of general health, social function, role 
limitations caused by emotional problems, and mental health. Scores for each scale 
range from 0 to 100. Higher scores indicate better health status. Overall physical and 
mental HRQOL can be assessed using the scores of the physical component summary 
(PCS) and mental component summary (MCS).14 
2.4 ROLE OF HRQOL IN PREDICTING RISK 
Whereas objective risk assessment of surgery focuses on mortality, survival, and 
morbidity, evaluating the HRQOL produces a subjective measure reflecting the impact 
of disease or its treatment on a patient’s physical and mental health. Studies show 
that objective functional measures and self-reported QOL are two independent 
measures.15 
Many instruments are available to measure HRQOL specific to different medical 
disciplines. In cancer research, most recent studies used well-validated cancer-specific 
QOL questionnaires. A review of the literature identified 59 different instruments 
used to measure the QOL of patients with cancer.16 The European Organization for 
Research and Treatment of Cancer’s Quality of Life Questionnaire-C30 and SF-36 are 
widely used as a cancer-specific and generic QOL instrument, respectively.16 
The utility of patient-reported outcome measures for risk prediction has recently 
garnered increasing interest. For example, HRQOL is associated with survival of 
patients with cancer after coronary bypass surgery as well as subsequent surgeries for 
lung cancer.8-10 Further, Pompili et al. found a significant association between the 
Clinic 2008 2009 2010 2011 2012 2013 2014 2015 
Stockholm    386 386 396 452 453 
Lund 28 474 498 501 483 466 518 451 
Göteborg 231 288 388 349 395 393 352 391 
Linköping 205 248 243 297 260 262 313 298 
Uppsala 156 132 26 56 43 312 309 305 
Umeå 34 10 135 143 155 160 177 225 
Örebro 93 81 125 134 131 109 149 150 
Karlskrona 9   119 118 102 98 73 
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preoperative physical components of HRQOL, overall survival, and cancer-specific 
survival of patients undergoing resection for early-stage NSCLC.17 This relation 
requires further investigation and discussion. A possible explanation of the 
association may be that the HRQOL reflects the unmeasurable effects of lung cancer 
and its treatment on a patient’s physical and emotional status.17 
Möller and Sartipy used the SF-36 questionnaire to analyze the association between 
self-reported QOL and outcomes of lung surgery based on data for a population of 
patients who underwent surgery at Karolinska University Hospital in Sweden 
between 2006 and 2008.10, 18 Two studies focused on the relationship between self-
reported QOL and survival after lung cancer surgery. In the first study, the 
investigators found postoperative declines of 10% in the PCS and MCS scores from 
preoperative baseline scores were associated with 18% and 13% higher risks of death, 
respectively.10 The second study assessed the prognostic value of HRQOL for 
evaluating long-term survival 6 months after lung cancer surgery (median follow-up, 
4 years).18 The results show that the PCS and MCS scores were significantly 
associated with survival, independent of baseline scores. A compelling finding is that 
MCS scores less than the mean of the age- and gender-matched normal population 
were associated with a 3-fold increase in the risk of death.18 
2.5 LUNG METASTASIS FROM CRC 
CRC is the third most commonly diagnosed cancer in males and the second in 
females, with a worldwide estimate of 1.4 million cases and 693,900 deaths every 
year.19 Approximately 25% of patients have metastatic disease at the time of initial 
diagnosis, and approximately 50% of patients with CRC will have metastasis. The two 
most common sites of metastatic growth are the liver and lungs, affecting 
approximately 35% and 5%–15% of patients, respectively.20 In Sweden, nearly 6000 
new cases of CRC are diagnosed each year.21 
Considerable progress has been made in improving therapy of CRC, including 
diagnosis and multidisciplinary treatment because of improvements in our 
understanding of oncogenic signaling pathways, discovery of new tumor-specific 
markers, and introduction of targeted therapy. These advances have improved the 
survival of patients with CRC as well as those with liver metastases. For example, 
patients with metastatic disease had a 5-year survival rate of approximately 25% 
compared with 50% at the time this review was accepted for publication.22, 23 
Resection of R0-resectable liver metastases of CRC was adopted in the mid-1990s as a 
curative treatment, and subsequently this modality has become widely accepted, 
although the supporting evidence is based entirely on retrospective observational 
studies. Similarly, pulmonary metastasectomy of CRC (PM-CRC) has become widely 
accepted in clinical practice to improve long-term survival.24, 25 Treasure et al. 
reviewed studies of pulmonary metastasectomy used to treat four common malignant 
tumors and found that although pulmonary metastasectomy appears beneficial for 
the management of metastasized germ cell tumors, the evidence is weak regarding 
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CRC, sarcomas, and melanomas because of an absence of randomized trials, 
comparative analyses, and selection bias.4 
Evidence indicating the benefits of PM-CRC is insufficient to generate an unequivocal 
clinical guideline for surgical indications or to demonstrate an influence on long-term 
survival. Such evidence comprises mainly retrospective studies and meta-analyses, 
but not randomized studies.26 
Evidence demonstrates the prognostic value of the variables as follows: disease-free 
interval (DFI), number and laterality of metastases, hilar and mediastinal lymph 
nodes metastasis, previous metastatic disease in the liver, staging of the primary 
tumor, prethoracotomy carcinoembryonic antigen (CEA) concentrations, KRAS status, 
carbohydrate antigen 19-9 (CA19-9), and location of the primary tumor.27-30 To our 
knowledge, few studies propose prognostic models incorporating these variables to 
improve the selection of patients who will benefit from surgery, although these 
models are not validated or widely applied.31 
A survey of current clinical practice among members of the European Society of 
Thoracic Surgery (ESTS) shows that approximately 40% of pulmonary 
metastasectomies with curative intent are performed using VATS.32 This approach is 
controversial because of the possibility of missing small lesions as well as the 
restriction of bimanual palpation through the surgical ports. A prospective, 
sequentially controlled study by Eckardt et al. found that several lesions that were 
undetected using imaging techniques were discovered via thoracotomy, but not using 
VATS. A significant proportion of these lesions are not benign (33% metastases and 
3% primary lung cancers).32 
The need for a randomized study on PM-CRC has increased because of variations in 
surgical practice, continuous pressure to expand the indications of surgical treatment, 
and absence of strong evidence on its effectiveness. The randomized, controlled 
Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) trial funded by Cancer 
Research UK was launched in March 2010, and recruitment continues.33 The 
objective of this trial is to study the effectiveness of pulmonary metastasectomy, 
focusing on clinical outcomes, overall survival, relapse-free survival, lung function, 
and patient-reported QOL.33 
2.6 VATS LOBECTOMY 
The development of minimally invasive surgery has dramatically changed numerous 
surgical subspecialties over the past three decades. The driving forces behind these 
developments are minimal surgical trauma and rapid postoperative recovery. 
VATS lobectomy was introduced at the beginning of the 1990s as an alternative to 
conventional thoracotomy. Since its introduction, the technique has gained 
worldwide recognition. The continuous endeavor to overcome post-thoracotomy 
pain, which is one of the most severe types of postoperative pain, was an important 
incentive responsible for the wide adoption of VATS lobectomy, particularly when 
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early reports from centers that frequently conduct VATS supported its feasibility and 
safety for treatment of early NSCLC.34-36 
The absence of standardization and definition of VATS for lobectomy has generated 
controversy about its advantages compared with traditional thoracotomy for treating 
NSCLC. The techniques vary between VATS with simultaneous stapling and hybrid 
video-assisted minithoracotomy with some rib retraction.37, 38 Consequently, 
authentic VATS lobectomy for treating patients with early-stage NSCLC is defined as 
minithoracotomy (4–8 cm), two 0.5-cm port incisions using a video camera as a 
guide, and conventional hilar dissection without rib retraction.6, 39 
Hansen et al. described the Copenhagen experience using a VATS lobectomy protocol 
that employs a standardized three-port anterior approach.40 Their study of the 
outcomes of approximately 1000 patients demonstrates the many advantages of this 
approach. The figure below demonstrates how the surgeon and assistant stand on the 
same side of the anterior side of the patient and view the same image, while the scrub 
nurse stands opposite. A 5-cm utility incision placed over the hilum in the 4th 
intercostal space anterior to the latissimus dorsi muscle (anterior incision) facilitates 
the dissection of hilar structures and easy control of major bleeding and rapid 
conversion if required. The camera-port is positioned lower down in the anterior 
axillary line at the level of the top of diaphragm, and the last 1.5-cm incision is 
posteriorly positioned at the same level as the camera-port under the scapula and 
anterior to the latissimus dorsi muscle. The same approach is suitable for resection of 
all lobes, and it is recommended to gently push the lung tissue, without grasping 
forceps, to minimize the risk of lung damage and postoperative air leaks.40 A review 
by McElnay et al. found a substantial increase in the number of VATS lobectomies, 
accompanied by improved safety after adoption of a standardized anterior program.41 
 
 
 
 
 
 
 
 
 
 
Standard anterior approach 
Reprinted with permission from CROCE 
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The feasibility of VATS lobectomy as a standard approach to treat lung cancer is the 
subject of investigations of a large series of national databases, large institutional 
studies, and meta-analyses. Although the evidence is based mainly on comparative 
nonrandomized studies, certain international guidelines recommend VATS lobectomy 
as the approach of choice for treating patients with stage I NSCLC.42 Vannucci and 
Gonzales in a literature review study found that VATS lobectomy is a safe procedure 
with lower complications, less post-operative pain and better post-operative quality of 
life, compared with thoracotomy. VATS has at least equivalent, if not better, post-
operative survival, compared with open surgery. While the thoracotomy approach has 
significantly higher node upstaging than VATS in four articles, the overall survival 
was not significantly different.43 In a recent national analysis in USA, Yang et al 
demonstrated noninferior long-term survival after VATS lobectomy for early stage 
NSCLC compared with open thoracotomy.44 
The superiority of VATS lobectomy over thoracotomy associated with short-term 
clinical outcomes is demonstrated by numerous studies. For example, the benefits 
include decreased postoperative pain, better QOL, fewer perioperative complications, 
improved lung function, improved immune responses, better outcomes for high-risk 
patients with poor lung function, and lower hospitalization costs.36, 45-50 However, 
other studies found that postoperative survival, complications, and long-term QOL 
are comparable with those of thoracotomy.36 
Technological advances and accumulated experience performing VATS surgery has 
spawned techniques that allow management of complex cases with results 
comparable to those of open surgery. Examples include bronchial sleeve, vascular 
sleeve, and tracheal/cranial resection. Contraindications to VATS lobectomy are 
relative, depending mainly on the surgeon’s experience. Absolute oncological 
contraindications remain similar for both approaches.43 
VATS causes less severe trauma, although the oncological principles of surgical 
resection of NSCLC are the same for thoracotomy and VATS. Consequently, several 
studies evaluated the efficacy of VATS lobectomy for radical resection of NSCLC and 
lymph-node upstaging.43, 44, 51 
In Sweden, the VATS technique has been used for many years to perform simple 
thoracic procedures such as lung biopsies, wedge resections, and pleurectomies. The 
VATS lobectomy program started in 2012, and the number of procedures performed 
annually has increased. However, according to ThoR,7 almost all patients who 
underwent the procedure from 2012–2015 were treated at one out of eight thoracic 
surgical centers. 
Uniportal VATS lobectomy, which has undergone development as minimally invasive 
thoracic surgery during the last 10 years, has generated increasing interest because of 
growing evidence regarding its feasibility for managing lung cancer and mediastinal 
tumors, lower postoperative pain, and improved patient satisfaction compared with 
multiportal VATS.43  
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Subxiphoid uniportal VATS lobectomy, microlobectomy with the VATS technique, 
and awake-VATS are examples of several ongoing developments in minimally 
invasive thoracic surgery, although further evidence of efficacy must be provided 
before they can be widely applied in clinical practice.52-54 
2.7 WEEKDAY OF SURGERY AND SURVIVAL AFTER PULMONARY RESECTION OF 
LUNG CANCER 
Medical subspecialties expanded extensively during the last decades because of 
revolutionary developments in medical science. These developments have 
substantially improved healthcare by achieving better early and late outcomes. 
However, insufficient continuous availability of highly qualified healthcare providers 
is generating new challenges and difficulties.55 
Many studies demonstrate poor clinical outcomes and mortality following admission 
of patients on the weekend compared with weekdays. There is compelling evidence 
supporting these results, which is particularly associated with patients with acute 
conditions.56 The results of studies conducted during the last decade conflict 
regarding the "weekday effect" on short- and long-term mortality associated with 
different surgical disciplines. For example, Aylin et al. conducted a large retrospective 
study of more than 4 million patients admitted for elective surgery in the United 
Kingdom and found a higher risk of mortality when the procedures were performed 
on Friday or during the weekend.57 Lagergren et al. conducted a study in Sweden 
that found worse 5-year all-cause and disease-specific mortality when elective surgery 
for esophageal cancer was performed later in the week.58 Several other studies 
conducted in different countries corroborate these results.59-61 However, a significant 
effect of surgery performed on weekdays on early- or long-term survival is not 
demonstrated by other large studies. For example, a study conducted in the 
Netherlands by Visser et al. failed to detect a significant difference in short- and long-
term oncological outcomes associated with performing esophagectomy on 
weekdays.62 Similarly, Dalén et al. conducted a large cohort study of patients in 
Sweden who underwent cardiac surgery, but was unable to uncover evidence of an 
association of the day of surgery with mortality.63 
We are unaware of any studies that exclusively investigated the influence of weekday 
on surgery for lung cancer. In Sweden, thoracic surgeons associated with eight 
thoracic surgery clinics perform the surgery, which in some clinics, is only performed 
by dedicated general thoracic surgeons. In general, the surgical resection of lung 
cancer is an elective procedure that is performed on weekdays. 
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3 AIMS OF THE THESIS 
 
The general aim of this thesis was to investigate several important clinical aspects of 
surgical resection of malignant tumors in the lung, which represents >70% of the 
number of GTS procedures. 
Study I 
To investigate the association between baseline self-reported HRQOL and long-term 
survival after thoracic surgery. 
Study II 
To evaluate long-term survival following PM-CRC at the Karolinska University 
Hospital and identification of possible prognostic factors to facilitate patient selection. 
Study III 
To describe overall survival after PM-CRC in Sweden and to validate a recent 
proposed risk prediction model in the Swedish population. 
Study IV 
To review the feasibility and safety of VATS lobectomy as an alternative approach to 
surgical treatment of early NSCLC by conducting a nationwide study in Sweden, 
comparing VATS with a thoracotomy approach in lobectomy procedures regarding 
their effects on long-term survival and early postoperative clinical outcomes. 
Study V 
To conduct a nationwide cohort to investigate the possibility of an association 
between the weekday of surgery and all-cause mortality following pulmonary 
resection of lung cancer. 
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4 PATIENTS AND METHODS 
4.1 ETHICAL CONSIDERATIONS 
The regional Human Research Ethics Committee in Stockholm, Sweden, approved all 
studies. 
4.2  STUDY DESIGN, POPULATION, AND DATA COLLECTION 
4.2.1 Study I 
A prospective population-based cohort study including patients scheduled for thoracic 
surgery at Karolinska University Hospital, Stockholm, Sweden, between 2006 and 
2008. Patients completed a preoperative (SF-36) questionnaire. Comorbidities were 
identified as follows; ischemic heart disease (history of angina pectoris, myocardial 
infarction, coronary artery bypass surgery or percutaneous coronary intervention), 
hypertension (high blood pressure requiring treatment), congestive heart disease 
(history of heart failure or ejection fraction <0.5), diabetes mellitus (diabetes 
requiring medication), peripheral vascular disease (history of claudication, carotid 
stenosis, or abdominal aneurysm), and cerebrovascular disease (history of stroke or 
transient ischemic attack). Smoking status was categorized into 3 groups as follows: 
current smoker (patient was an active smoker or quit smoking within 1 year of 
surgical procedure), former smoker (patient stopped smoking more than one year 
before surgery), and never smoker. The tumor stage was divided into two categories, 
stage 0 to I and stage II to III. The extent of lung resection was categorized into two 
groups, sublobar (wedge) resection and lobectomy/pneumonectomy. The patients 
were categorized with higher or lower QOL compared with that of a reference 
population. The PCS and MCS scores for each patient were compared with the 
respective scores of an age- and sex-matched reference population. Patients’ data 
were collected from institutional databases and patients’ charts. 
4.2.2 Study II 
An observational population-based cohort study included all patients with CRC who 
underwent surgical resection of pulmonary metastases at Karolinska University 
Hospital, Stockholm, Sweden, between January 1, 2004, and December 31, 2015. 
Patients’ data were collected from institutional databases and patients’ charts. 
Comorbidity was defined as any medical condition with ongoing treatment or one 
that might affect prognosis, such as hypertension, atrial fibrillation, coronary artery 
disease, diabetes, or stroke. Smoking status was categorized into the groups as 
follows: current smoker, patient was an active smoker or quit smoking within 1 
month of surgery; former smoker, patient stopped smoking more than 1 month 
before surgery; never smoker, patient who never smoked; and smoking status 
unknown. Lung resection was classified as lobectomy vs sublobar resection (wedge 
resection). 
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4.2.3 Study III 
An observational nationwide population-based cohort study that included all patients 
registered in ThoR who underwent surgical resection of pulmonary metastases from 
CRC between January 1, 2009 and December 31, 2015. Comorbidity and smoking 
status was identified as in Study II. The study created a prognostic index and risk 
categories, following a recent Japanese study,31 which employed the preoperative 
prognostic factors as follows: age ≥70 years, DFI <2 years, extrathoracic lesion, 
abnormal prethoracotomy CEA level, and ≥3 pulmonary metastases. Patients were 
assigned to one of three risk categories based on the number of preoperative 
prognostic factors (0 factor, low risk; 1–2 factors, moderate risk; and ≥3 factors, high 
risk). In this study, prethoracotomy CEA data were not available, and the calculations 
of the prognostic index assumed that all patients had normal CEA concentrations. 
4.2.4 Study IV 
An observational population-based cohort study. The study included all patients 
registered in ThoR who underwent lobectomy for NSCLC between January 1, 2012, 
and December 31, 2015. Comorbidity and smoking status was identified as in Study 
II. All patients who underwent VATS lobectomy at Karolinska University Hospital 
were included in the VATS group, and patients who underwent thoracotomy at other 
hospitals were included in the thoracotomy group. The study excluded patients who 
underwent thoracotomy at the Karolinska Institute during the study period as well as 
the few patients (n = 14) who underwent VATS lobectomy at other hospitals. Among 
the 3013 patients who underwent lung resection for NSCLC, 1412 were excluded 
from the study for the reasons as follows: 1072 no lobectomy, 220 open lobectomy at 
Karolinska University Hospital, and 120 extended lobectomy procedures (Figure 10). 
4.2.5 Study V 
A nationwide (Sweden) observational population-based cohort study. The study 
included all patients registered in ThoR who underwent pulmonary resections for 
lung cancer between January 1, 2009 and December 31, 2015. Comorbidity was 
identified as in Study II. Smoking status was defined as follows: 1. Current smoker, if 
the patient was an active smoker or stopped smoking within 1 month from surgery 
and 2. Other, the remaining patients. Lung resection was classified as lobectomy or 
sublobar resection (wedge resection). The very few patients in Sweden who 
underwent surgery on a weekend or a public holiday were excluded. 
4.3 OUTCOME MEASURES 
4.3.1 Study I 
Association between baseline self-reported HRQOL (PCS and MCS) and long-term 
survival after thoracic surgery. 
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4.3.2 Study II 
The primary outcome measure was long-term survival after PM-CRC. 
4.3.3 Study III 
The outcome measure was overall survival after PM-CRC in Sweden. 
4.3.4 Study IV 
The primary outcome measure was long-term survival after VATS lobectomy 
compared with open thoracotomy lobectomy in patients with early-stage NSCLC. The 
secondary outcomes were assessment of early clinical postoperative outcomes and 
complications associated with these surgeries. 
4.3.5 Study V 
All-cause mortality after pulmonary resection for lung cancer associated with the 
weekday of surgery. 
4.4 STATISTICAL ANALYSIS 
Statistical analyses were performed using Stata version 14.1 in Study I, Stata 14.2 in 
Study II, and Stata 15.1 in Studies III–V (Stata Corp LP, College Station, TX, United 
States) and R version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria) 
in Study IV. 
4.4.1 All studies 
Baseline characteristics are described as frequencies and percentages for categorical 
variables and as the mean and standard deviation (SD) for continuous variables. 
Person-time in days was counted from the date of surgery until the date of death or 
the end of follow-up. The Kaplan–Meier method was used to calculate cumulative 
survival. 
4.4.2 Study I 
Cox proportional hazards regression was used with and without multivariable 
adjustment to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) to 
evaluate the significance of the association between preoperative QOL and long-term 
survival. Multiple imputation using chained equations was employed to handle 
missing data. Twenty-five data sets were imputed, and estimates from these data sets 
were combined.64 
4.4.3 Study II 
Cox proportional hazards regression was used with and without multivariable 
adjustment to estimate hazard ratios (HR) and 95% CIs of the association between 
patients’ characteristics and all-cause mortality. 
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4.4.4 Study III 
The restricted mean survival time (RMST) was estimated in the three risk categories 
and was calculated as the difference (95% CI) in survival compared with the low-risk 
category. Cox proportional hazards regression was used to estimate HRs and 95% CIs 
of the association between a risk category and all-cause mortality. In this study, DFI 
data was missing for 188 patients (25%). We handled missing data using multiple 
imputation by chained equations.64 Fifty data sets were imputed, and estimates from 
these data sets were combined. 
4.4.5 Study IV 
The RMST and the difference in survival between patients who underwent open 
thoracotomy or VATS lobectomy were calculated. The inverse probability of 
treatment weighting (IPTW) was used to create a balance in the baseline patients’ 
characteristics between the two groups. The weights were derived from propensity 
scores estimated using generalized boosted regression modeling. The following 
variables were used in the estimation of propensity scores: age, sex, body mass index, 
heart disease, diabetes, stroke, chronic kidney disease, other comorbidities, 
performance status, preoperative forced expiratory volume per second, prior thoracic 
surgery, prior sternotomy, smoking status, adjuvant chemo- or radiotherapy, and 
pathological cancer stage. The balance between treatment groups was assessed 
through the reporting of standardized mean differences. A standardized difference 
≤0.1 was considered ideal, and a standardized difference ≤0.2 was considered 
acceptable. Cox proportional hazards regression was used to estimate HRs and 95% 
CIs. 
4.4.6 Study V 
The patients in the study were categorized into groups according to the weekday of 
surgery. Crude and multivariable adjusted Cox regression models were fitted to 
estimate HRs and 95% CIs of the association between weekday of surgery and 
survival. Patients who underwent surgery on a Monday served as the reference 
category. Patients’ ages were modeled using restricted cubic splines, and other 
variables were included as categorical terms. The RMST was reported by weekday at 
1 and 5 years, and the difference in RMST (95% CI) was determined using Monday 
as the reference category. 
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OVERVIEW OF THE STUDY DESIGNS AND METHODS 
 
Study I Study II Study III Study IV Study V 
Design 
Observational, population-
based (Karolinska) 
Observational, nationwide (ThoR) 
Cohort Adults, GTS Adults, PM-CRC 
Adults, VATS 
and 
thoracotomy 
lobectomy 
Adults, 
surgery for 
NSCLC 
Period 2006–2008 2004–2015 2009–2015 2012–2015 2009–2015 
Follow-up 31 Jan 2016 15 Jan 2017 17 Apr 2017 
Outcomes Overall survival 
Overall survival, 
postoperative 
outcomes 
Overall 
survival 
Statistical 
methods 
Multivariable 
survival 
analysis (Cox 
regression), 
multiple 
imputation 
Multivariable 
survival 
analysis (Cox 
regression) 
Multivariable 
survival 
analysis (Cox 
regression), 
RMST, multiple 
imputation 
Multivariable 
analysis (Cox 
and logistic 
regression), 
IPTW 
Multivariable 
survival 
analysis (Cox 
regression), 
RMST 
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5 RESULTS 
5.1 STUDY I 
5.1.1 Patients’ characteristics and survival 
This study included 249 patients (mean age 63.8 years, 48 women). Patients’ 
characteristics are shown in Table 1. Higher and lower summary scores (PCS and 
MCS) of the patients were compared with those of an age- and sex-matched 
population. 
Among patients with lower scores, 43% (108 of 249) had lower PCS scores and 72% 
(180 of 249) had lower MCS scores. The median follow-up was 8 years, and 48% 
(119) of patients died during the study period. Among the patients with lower PCS 
and MCS scores, 60 % (65 of 108) and 52% (93 of 180) died, respectively. Among 
the patients with higher PCS and MCS scores, 38% (54 of 141) and 38% (26 of 69) 
died, respectively. The SF-36 subscale and summary scores for the total population 
and the age- and sex-matched reference population are shown in Table 2. 
PCS scores lower than the reference were significantly associated with higher 
mortality in the crude (HR, 1.93; 95% CI, 1.35–2.77, p < 0.001) and multivariable 
adjusted analyses (HR, 2.02; 95% CI, 1.34–3.06, p 0.001) (Table 3, Figure 1). 
However, an MCS score lower than the reference was not significantly associated 
with mortality according to the crude and multivariate adjusted analyses (HR, 1.52; 
95% CI, 0.99–2.36, p = 0.058 and HR, 1.32; 95% CI, 0.84–2.08, p = 0.233, 
respectively) (Table 3, Figure 2). 
For each 5-point decrease in the baseline PCS score, the risk of long-term all-cause 
mortality increased by 12% (p = 0.005). The sensitivity analyses were repeated with 
patients categorized according to a 5% difference in the PCS score compared with the 
reference populations. This adjusted multivariable analysis revealed a significant 
association of the PCS score, which was 5% lower than the reference, with mortality 
(adjusted HR, 1.87; 95% CI, 1.2–2.84, p = 0.003). 
The association between a low PCS score and mortality in selected clinically relevant 
subgroups was investigated. The data consistently showed that a PCS score lower 
than reference was significantly associated with increased postoperative long-term 
mortality (Figure 3). 
Patients with low PCS scores were stratified into subgroups of cancer stage as follows: 
stage 0, stage I, and stages II and III. The analysis was adjusted only for age because 
of the limited number of patients and mortality in each subgroup. The results are as 
follows: stage 0, 79 patients, 26 deaths, age-adjusted HR, 1.51 (95% CI, 0.70–3.26; p 
= 0.294); stages II to III, 45 patients, 31 deaths, age-adjusted HR, 2.08 (95% CI, 
1.00–4.34; p = 0.051) and stage I, 125 patients, 62 deaths, age-adjusted HR, 2.02 
(95% CI, 1.22–3.32; p = 0.006); and the multivariable-adjusted HR was 2.22 (95% 
CI, 1.22–4.05; p = 0.009).  
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5.2 STUDY II 
This study included 184 patients (mean age 64.8 years, 46% women). Patients’ 
characteristics are shown in Table 4. Pulmonary resection was performed using VATS 
(46% of patients). Sublobar resection (wedge resection) was the dominant type of 
resection (78% of patients). Rectal cancer was the primary tumor among 59% of 
patients followed by colon cancer (20%) and sigmoid cancer (21%). Most patients 
were classified as performance status 0, and 29% of patients underwent preoperative 
positron emission tomography–computed tomography (PET-CT). The number of 
procedures increased during the study period from one in 2004 to 34 in 2015, 
peaking at 45 in 2014 (Figure 4). 
The median follow-up time was 3.2 years, and 36% (66 of 184) of patients died 
during the study period. The estimated 5-years survival rate was 60% (95% CI, 50%–
68%) (Figure 5). Survival within 95% CI of patients who underwent PM-CRC was 
compared with the expected survival of age- and sex-matched persons from the 
Swedish population. Figure 6 shows significant divergence of the survival curves after 
the 1-year follow-up, demonstrating shorter survival of members of the metastasis 
group. 
5.2.1 Prognostic factors of survival 
A CEA concentration >4 µg/L was the only significant prognostic factor associated 
with high mortality in the crude (HR, 2.30; 95% CI, 1.09–4.85; p = 0.029) and age- 
and sex-adjusted (HR, 2.46; 95% CI, 1.15–5.26; p = 0.020) analyses. Other relevant 
characteristics were not significantly associated with mortality (crude or adjusted 
analysis) (Table 5). 
 
 
 
 
 
 
 
 
 
Figure 4 
Number of operations (PM-CRC) per 
year during the study period. 
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Table 4. Characteristics of patients (n = 184) with colorectal cancer who underwent 
pulmonary metastasectomy. 
Variable N (%) 
Age, year, mean (SD) 64.8 (10.2) 
Sex  
Male 99 (54%) 
Female 85 (46%) 
Body mass index, kg/m2, mean (SD) 26.3 (4.1) 
Comorbidity, any 70 (38%) 
Performance status (ECOG)  
0 (Asymptomatic) 172 (93%) 
1 (Symptoms, but fully active) 12 (7%) 
Smoking status  
Never smoker 75 (41%) 
Former smoker 15 (8%) 
Current smoker 72 (39%) 
Unknown 22 (12%) 
PET-CT preoperatively 54 (29%) 
Location, primary tumor  
Colon 37 (20%) 
Sigmoid 39 (21%) 
Rectum 108 (59%) 
Primary CRC stage  
I 9 (4.9%) 
II 46 (25%) 
III 86 (47%) 
IV 31 (17%) 
Unknown 12 (6.5%) 
Adjuvant radiotherapy 4 (2%) 
Adjuvant chemotherapy 41 (22%) 
Other metastases 91 (49%) 
Liver 57 (31%) 
Lung 30 (16%) 
Other 4 (2%) 
Disease-free interval  
<24 months 95 (52%) 
≥24 months 88 (48%) 
Unknown 1 (0.5%) 
CEA  
<4 µg/L 94 (51%) 
≥4 µg/L 17 (9%) 
Unknown 73 (40%) 
Extent of resection  
Sublobar resection 144 (78%) 
Lobectomy 40 (22%) 
  
VATS 85 (46%) 
Number of metastases  
1 141 (77%) 
2 29 (16%) 
≥3 14 (8%) 
Size of pulmonary metastases (largest lesion)  
<20 mm 126 (68%) 
≥20 mm 50 (27%) 
Unknown 8 (4%) 
Hospitalization, days, mean (SD) 5.5 (1.6) 
CEA = carcinoembryonic antigen, CRC = colorectal cancer, ECOG = Eastern Cooperative 
Oncology Group, VATS = Video-assisted thoracoscopic surgery, PET-CT = positron emission 
tomography–computed tomography  
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Figure 5. Kaplan–Meier analysis of estimated overall survival of patients with 
colorectal cancer who underwent pulmonary metastasectomy . 
  
Table 5. Prognostic factors of survival of patients who underwent pulmonary metastasectomy after 
colorectal cancer. 
 
Crude 
HR (95% CI) 
p 
Age- and sex 
adjusted HR (95% CI) 
p 
Age >65 years 1.17 (0.71-1.90) 0.539 1.18 (0.72-1.94)* 0.508 
Female 1.07 (0.66-1.73) 0.792 1.08 (0.67-1.76)** 0.745 
Any comorbidity 1.58 (0.97-2.60) 0.069 1.56 (0.94-2.59) 0.083 
Other metastases (liver or 
lung) 1.23 (0.76-2.00) 0.407 1.26 (0.77-2.06) 0.361 
Liver metastases 1.45 (0.87-2.42) 0.151 1.45 (0.87-2.43) 0.156 
More than one pulmonary 
metastasis 1.39 (0.82-2.35) 0.216 1.42 (0.84-2.41) 0.189 
Size of pulmonary metastases 
≥20 mm 
1.00 (0.59-1.67) 0.990 0.98 (0.58-1.65) 0.945 
Disease-free interval <24 
months 
1.11 (0.68-1.81) 0.668 1.14 (0.70-1.87) 0.595 
CEA > 4 µg/L 2.30 (1.09-4.85) 0.029 2.46 (1.15-5.26) 0.020 
*Only adjusted for sex **Only adjusted for age 
HR = hazard ratio, CI = confidence interval, CEA = carcinoembryonic antigen 
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Figure 6. Overall survival (red line) and 95% confidence interval (red dashed lines) 
of patients who underwent pulmonary metastasectomy for colorectal cancer. 
Expected survival (black line) of an age- and gender-matched Swedish population. 
 
5.3 STUDY III 
5.3.1 Patients’ characteristics 
This study included 726 patients (mean age 65.8 years, 43% women) who underwent 
929 surgical procedures. For patients with multiple entries in the register, only the 
first record was used. The primary CRC was located in the colon or sigmoid in 59% of 
patients and in the rectum of 41% of patients. At least three metastases were found in 
6% of patients, and 25% of patients had extrathoracic metastases. Sublobar resection 
and VATS were used to treat 81% and 34% of patients, respectively (Table 6). 
5.3.2 Number of surgeries 
The number of surgeries increased during the study period. However, the increase in 
the number of patients operated must be interpreted in light of the fact that ThoR did 
not include all hospitals in Sweden until 2013. 
5.3.3 Risk categories 
The patients were classified into the risk categories (described above) as follows: low 
risk (n = 166), moderate risk (n = 558), and high risk (n = 32). Univariate analysis 
of preoperative prognostic factors in this model revealed that only the number of 
metastases (≥3) was significantly associated with all-cause mortality (HR, 2.47; 95% 
CI, 1.65–3.68, p<0.001). Baseline patients’ characteristics according to risk category 
are shown in Table 7.  
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5.3.4 Survival outcomes 
During the study period, 35% (268 of 756) of patients died, the median follow-up 
was 2.9 years, and 5-year overall survival was 56% (95% CI, 51%–60%) (Figure 8). 
The results of a Cox regression model with risk category as the only independent 
variable revealed that the HRs of the moderate- and high-risk categories compared 
with the low-risk category were 1.94 (95% CI, 1.38–2.72, p<0.001) and 4.35 (95% 
CI, 2.49–7.62, p<0.001), respectively, (C-statistic, 0.58) (Figure 9). The difference in 
RMST at various follow-up times between the moderate- and high-risk categories and 
the reference category (low-risk category) is shown in Table 8. At 2 years, the 
difference in RMST is 1 month in the moderate versus low risk group(p<0.001) and 
2 months in the high versus low risk group (p<0.001).This differences increase 
significantly at 5 years to 6 months and 1.5 between moderate versus low risk group 
and high versus low risk group, respectively. 
Patients who underwent VATS procedures have better survival than patients who 
underwent thoracotomy procedures in an analysis adjusted for risk category (HR 
0.73, 95%CI: 0.55-0.97, p=0.028). Further, no difference in survival between the 
patients regarding extent of lung resection (lobectomy versus wedge resection) in an 
analysis adjusted for risk category (HR 1.29, 95% CI: 0.97-1.72, p=0.078). 
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Table 6. Characteristics of patients (n = 756) with CRC who underwent pulmonary 
metastasectomy. 
Variable N (%) % missing 
Age, year, mean (SD) 65.8 (10.2) - 
Sex  - 
Male 430 (57%)  
Female 326 (43%)  
Body mass index, kg/m2, mean (SD) 26.5 (4.53) 8.6 
Comorbidity, none 407 (54%) - 
Heart disease 67 (9%) - 
Diabetes 57 (8%) - 
History of stroke/TIA 30 (4%) - 
Chronic kidney disease 16 (2%) - 
Other comorbidity 292 (39%) - 
Smoking status  9.3 
Never smoker 377 (55%)  
Former smoker 143 (21%)  
Smoker 64 (9%)  
Unknown 102 (15%)  
Performance status (ECOG)  - 
0 (Asymptomatic) 662 (88%)  
1 (Symptoms, but fully active) 94 (12%)  
Adjuvant radiotherapy 26 (4%) 4.4 
Adjuvant chemotherapy 130 (18%) 4.5 
PET-CT preoperative 309 (46%) 10 
Extent of resection  - 
Sublobar resection 616 (81%)  
Lobectomy 140 (19%)  
VATS 258 (34%) - 
Location, primary tumor  - 
Colon/Sigmoid 447 (59%)  
Rectum 309 (41%)  
Disease-free interval  25 
<24 months 258 (45%)  
≥24 months 310 (55%)  
≥3 metastases 44 (6%) - 
Synchronous metastases 86 (14%) 21 
Other metastases 237 (34%) 9.1 
Extra-thoracic metastases 188 (25%) - 
ECOG = Eastern Cooperative Oncology Group, VATS = Video-assisted thoracoscopic surgery, PET-
CT = positron emission tomography–computed tomography 
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Table 7. Risk categories and characteristics of patients (n = 756) with CRC who underwent 
pulmonary metastasectomy. 
 Risk category  
Variable 
Low 
(n = 166) 
Moderate 
(n = 558) 
High 
(n = 32) 
p value 
Age, year, mean (SD) 60.4 (7.98) 67.1 (10.2) 71.8 (9.69) <0.001 
Sex    0.564 
Male 100 (60%) 311 (56%) 19 (59%)  
Female 66 (40%) 247 (44%) 13 (41%)  
Body mass index, kg/m2, 
mean (SD) 
26.9 (4.68) 26.5 (4.49) 25.3 (4.28) 0.184 
Comorbidity, none 95 (57%) 291 (52%) 21 (66%) 0.202 
Heart disease 8 (5%) 58 (10%) 1 (3%) 0.043 
Diabetes 10 (6%) 46 (8%) 1 (3%) 0.399 
History of stroke/TIA 2 (1%) 27 (5%) 1 (3%) 0.106 
Chronic kidney disease 2 (1%) 14 (3%) 0 (0%) 0.412 
Other comorbidity 62 (37%) 220 (39%) 10 (31%) 0.607 
Smoking status    0.008 
Never smoker 82 (56%) 280 (55%) 15 (50%)  
Former smoker 22 (15%) 113 (22%) 8 (27%)  
Smoker 24 (16%) 40 (8%) 0 (0%)  
Unknown 18 (12%) 77 (15%) 7 (23%)  
Performance status (ECOG)    0.300 
0 (Asymptomatic) 151 (91%) 484 (87%) 27 (84%)  
1 (Symptoms, but fully 
active) 
15 (9%) 74 (13%) 5 (16%)  
Adjuvant radiotherapy 6 (4%) 19 (4%) 1 (3%) 0.988 
Adjuvant chemotherapy 27 (17%) 94 (18%) 9 (29%) 0.256 
PET-CT preoperatively 70 (49%) 232 (46%) 7 (23%) 0.024 
Extent of resection    0.833 
Sublobar resection 137 (83%) 454 (81%) 25 (78%)  
Lobectomy 29 (17%) 104 (19%) 7 (22%)  
VATS 55 (33%) 196 (35%) 7 (22%) 0.293 
Location, primary tumor     
Colon/Sigmoid 89 (54%) 341 (61%) 17 (53%) 0.176 
Rectum 77 (46%) 217 (39%) 15 (47%) 0.176 
Disease-free interval*    <0.001 
<24 months 0 (0%) 233 (54%) 25 (96%)  
≥24 months 114 (100%) 195 (46%) 1 (4%)  
≥3 metastases 0 (0%) 28 (5%) 16 (50%) <0.001 
Synchronous metastases 8 (6%) 70 (16%) 8 (30%) 0.002 
Other metastases 19 (13%) 192 (38%) 26 (84%) <0.001 
Extra-thoracic metastases 0 (0%) 162 (29%) 26 (81%) <0.001 
ECOG = Eastern Cooperative Oncology Group, VATS = Video-assisted thoracoscopic surgery, 
PET-CT = positron emission tomography-computed tomography  
*Only reported for patients without missing information 
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Figure 7. Numbers of annual surgeries. 
 
  
Table 8. Differences in restricted mean survival time according to risk category. 
 
Restricted mean survival difference (95% CI), days 
 
Risk category 
Follow-up 
Low 
(n = 166) 
Moderate 
(n = 558) 
p 
value 
High 
(n = 32) 
p 
value 
1 year Reference -5 (-8 to -2) 0.003 -9 (-25 to 8) 0.306 
2 years Reference -28 (-42 to -14) <0.001 -64 (-117 to -10) 0.019 
3 years Reference -74 (-106 to -42) <0.001 
-199 (-306 to -
92) 
<0.001 
4 years Reference -137 (-192 to -82) <0.001 
-382 (-546 to -
218) 
<0.001 
5 years Reference 
-198 (-281 to -
115) 
<0.001 
-537 (-768 to -
306) 
<0.001 
CI = confidence interval  
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Figure 8. Kaplan–Meier analysis of estimated overall survival of patients with 
colorectal cancer who underwent pulmonary metastasectomy. 
 
 
Figure 9. Influence of risk category on the results of Kaplan–Meier analysis of 
estimated overall survival of patients with colorectal cancer who underwent 
pulmonary metastasectomy. 
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5.4 STUDY IV 
5.4.1 Patients’ characteristics and numbers of surgeries 
This study included 1601 patients (mean age 67.7 years) with NSCLC who 
underwent thoracotomy (n = 1316) or VATS lobectomy (n = 285) (Figure 10). The 
percentage of women (54%) was higher in the VATS group. There was no difference 
in the distribution of comorbidities between the two groups, although more 
advanced-stage patients underwent thoracotomy. The baseline characteristics of the 
two groups were balanced with the IPTW, and the standardized mean difference 
among all variables was <0.1 (Table 9). 
The number of VATS lobectomies increased during the study period, and in 2015, 
VATS was the dominant lobectomy procedure at Karolinska University Hospital (123 
VATS vs 68 thoracotomies) (Figure 11). 
Most patients in the open thoracotomy and VATS groups did not have postoperative 
complications (83% vs 86%, respectively; p = 0.41. However, significantly shorter 
drain times, fewer blood transfusions, shorter hospitalizations, fewer reoperations, 
and fewer cases of postoperative pneumonia were experienced by the VATS group. 
The 30- and 90-day mortality rates of the open thoracotomy and VATS groups were 
0.6% vs 0.7% (p = 0.38) and 1.7% vs 0.3% (p = 0.09), respectively (Table 10). A 
higher percentage of patients in the VATS group were discharged to rehabilitation 
compared with the thoracotomy group (63% vs 30%, respectively; p<0.001). 
Median follow-up times were 2.6 years and 2.3 years for the open thoracotomy and 
VATS groups, respectively. The overall 1- and 5-year survival rates were 92% vs 97% 
and 63% vs 78% in the open thoracotomy and VATS group, respectively (HR [95% 
CI], 0.47 [0.33–0.68], p<0.001 (Figure 12). These results were confirmed using a 
standard multivariable-adjusted Cox regression model applied to the unweighted 
sample and as well as a “doubly robust” covariate-adjusted weighted Cox regression 
model. Cox regression analysis of a subset of patients restricted to pathological stages 
I-IIA showed that patients who underwent VATS lobectomy survived significantly 
longer (HR 0.59, CI 95% [0.39-0.88], p = 0.009). 
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Figure 10. Study inclusion flowchart. 
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Table 9. Baseline characteristics of patients (n = 1601) who underwent open thoracotomy or 
minimally invasive VATS lobectomy for lung cancer in Sweden, 2012–2015: inverse probability of 
treatment weighting. 
 Unweighted  IPTW  
 Open VATS SMD Open* VATS* SMD 
n 1316 285  1571.1 1157.4  
Age, years, mean (SD) 67.7 (8.6) 67.7 (8.3) 0.001 67.7 (8.6) 67.7 (8.0) 0.004 
Female 716 (54) 185 (65) 0.215 876.0 (56) 655.5 (57) 0.018 
BMI, kg/m2, mean (SD) 26.4 (4.7) 25.4 (4.4) 0.222 26.2 (4.7) 26.0 (4.3) 0.052 
No comorbidity  626 (48) 118 (41) 0.124 734.0 (47) 529.5 (46) 0.019 
Heart disease 197 (15) 46 (16) 0.032 233.6 (15) 185.6 (16) 0.032 
Diabetes 123 (9.3) 22 (7.7) 0.058 141.9 (9.0) 94.1 (8.1) 0.032 
Prior stroke/TIA 69 (5.2) 10 (3.5) 0.085 79.6 (5.1) 51.4 (4.4) 0.029 
Chronic Kidney Disease 39 (3.0) 3 (1.1) 0.137 42.6 (2.7) 16.4 (1.4) 0.091 
Other comorbidity 526 (40) 141 (50) 0.192 646.9 (41) 505.9 (44) 0.051 
Performance status >0 482 (37) 75 (26) 0.223 553.8 (35) 370.6 (32) 0.068 
Preoperative FEV1, liter, 
mean (SD) 
2.3 (0.67) 2.2 (0.66) 0.130 2.3 (0.67) 2.3 (0.65) 0.011 
Prior thoracic surgery 47 (3.6) 12 (4.2) 0.033 57.8 (3.7) 31.2 (2.7) 0.056 
Prior sternotomy 25 (1.9) 11 (3.9) 0.117 32.2 (2.0) 26.4 (2.3) 0.016 
Current smoker 367 (28) 98 (34) 0.141 453.1 (29) 362.0 (31) 0.053 
Preoperative radiotherapy 34 (2.6) 1 (0.4) 0.186 36.0 (2.3) 13.2 (1.1) 0.089 
Preoperative chemotherapy 46 (3.5) 3 (1.1) 0.164 49.8 (3.2) 20.0 (1.7) 0.094 
Stage**   0.246   0.066 
   IA 543 (41) 115 (40)  649.1 (41) 497.8 (43)  
   IB 291 (22) 89 (31)  365.7 (23) 285.5 (25)  
   IIA 207 (16) 39 (14)  241.8 (15) 161.1 (14)  
   IIB 119 (9.0) 15 (5.3)  134.3 (8.5) 91.5 (7.9)  
   IIIA-X 156 (12) 27 (9.5)  180.2 (11) 121.5 (11)  
Numbers and percentages are indicated as n (%), unless otherwise noted. 
FEV1 = forced expiratory volume in one second, IPTW = inverse probability of treatment 
weighting, SD = standard deviation, SMD = standardized mean difference, TIA = transient 
ischemic attack, VATS = video-assisted thoracoscopic surgery,  
*The total number of patients in each group is not an integer owing to IPTW. 
**Pathological stage 
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Table 10. Postoperative events and complications after open thoracotomy or minimally invasive 
VATS lobectomy for lung cancer after IPTW. 
  
Total Open VATS 
Odds Ratio 
(95% CI) 
p value 
No complication 84% 83% 86% 1.20 (0.78-1.87) 0.41 
Drain removal on day 1 65% 21% 54% 0.23 (0.17-0.31) <0.001 
Reoperation 2.8% 3.8% 1.4% 0.35 (0.14-0.93) 0.03 
Transfusion 3.5% 5.0% 1.4% 0.27 (0.10-0.71) 0.008 
Pneumothorax and new 
chest tube 
3.4% 2.9% 4.2% 1.48 (0.69-3.18) 0.32 
Arrhythmia 4.2% 4.9% 3.3% 0.65 (0.25-1.70) 0.38 
Stroke/TIA 0.3% 0.4% 0.2% 0.45 (0.05-3.80) 0.47 
Myocardial infarction 0.2% 0.3% 0 - - 
Wound infection 0.4% 0.5% 0.2% 0.43 (0.05-3.52) 0.43 
Pneumonia 3.4% 5.5% 0.6% 0.11 (0.03-0.46) 0.002 
Empyema 0.3% 0.4% 0.2% 0.53 (0.06-4.58) 0.57 
Lymph leak 0.2% 0.3% 0 - - 
Pulmonary embolism 0.1% 0.2% 0 - - 
Reintubation 0.5% 0.7% 0.3% 0.44 (0.06-3.53) 0.44 
Recurrence nerve 
paralysis 
0.3% 0.5% 0 - - 
Phrenic nerve paralysis 0 0 0 - - 
Other complication 5.0% 3.6% 6.7% 2.00 (1.04-3.82) 0.04 
Death within 30 days 0.6% 0.7% 0.3% 0.39 (0.05-3.10) 0.38 
Death within 90 days 1.1% 1.7% 0.3% 0.17 (0.02-1.27) 0.09 
VATS = video-assisted thoracoscopic surgery, CI = confidence interval, SD = standard deviation 
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Figure 11. Numbers of annual surgeries. 
The upper panel shows the number of surgeries per year. The number of VATS 
lobectomies increased during the study period, although the number of open 
thoracotomies was constant. The lower panel shows the numbers of lobectomies 
performed annually at Karolinska University Hospital and at the end of the study 
period. VATS lobectomy was performed more frequently than open thoracotomy. 
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Figure 12. Survival after open thoracotomy or VATS. 
The figure shows open thoracotomy (black line) or VATS lobectomy (red line). The 
group of patients who underwent open thoracotomy lobectomy (black line) served as 
the reference group. Note that the numbers of patients at risk shown below the graph 
are not necessarily integers owing to IPTW. 
HR = hazard ratio, CI = confidence interval, VATS = video-assisted thoracoscopic 
surgery 
 
5.5 STUDY V 
5.5.1 Patients’ characteristics and number of surgeries 
This study included 4528 patients who underwent pulmonary resection for lung 
cancer in Sweden between 2009 and 2015 (mean age, 66.8 years (SD = 9.3); 55%, 
women; and 1311 (29%) smokers). Age, sex, and smoking status were not 
significantly different among the groups over the weekdays. Patients who were 
operated on Wednesday more frequently underwent preoperative radiotherapy. 
Patients with performance status = 0, compared with 1 or 2, underwent VATS more 
frequently on Fridays. In general, patients’ baseline characteristics (Table 11) were 
similarly distributed through the week.  
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The numbers of surgeries performed on Monday, Tuesday, Wednesday, Thursday, 
and Friday were as follows: 1137 (25%), 1018 (22%), 1001 (22%), 889 (20%), and 
483 (11%), respectively. 
5.5.2 Survival outcomes 
The median follow-up time was 2.9 years (mean, 3.3; SD, 2.0 years). The numbers of 
deaths per person years for each weekday were 387/3738 on Monday, 355/3452 on 
Tuesday, 369/3317 on Wednesday, 317/2946 on Thursday, and 170/1513 on Friday. 
The annual risk of death was 10%–11%, regardless of the weekday of surgery. 
Compared with Monday, the crude HRs for all-cause mortality (95% CI) were 0.99 
(0.86–1.15), 1.08 (0.93–1.24), 1.04 (0.90–1.21), and 1.07 (0.89–1.28) for Tuesday, 
Wednesday, Thursday, and Friday, respectively. The adjusted HRs for all-cause 
mortality (95% CI) compared with Monday were 0.98 (0.85–1.13), 1.03 (0.89–1.19), 
0.99 (0.85–1.15), and 1.04 (0.87–1.25) for Tuesday, Wednesday, Thursday, and 
Friday, respectively. There was no significant difference between crude or 
multivariable adjusted risks for all-cause mortality as a function of weekday, and 
there was no significant difference in RMST associated with the weekday of surgery 
at the 1- and 5-year follow-up examinations (Table 13, Figure 11). 
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Table 11. Patients’ baseline characteristics. 
 
Total 
population Mon Tue Wed Thu Fri p 
N (%) 4528 1137 (25%) 1018 (22%) 1001 (22%) 889 (20%) 483 (11%)  
Age, years, mean 
(SD) 66.8 (9.3) 67.1 (9.2) 66.5 (9.3) 66.6 (9.8) 66.7 (9.3) 67.1 (8.6) 0.553 
Female sex 2499 (55.2) 645 (56.7) 576 (56.6) 554 (55.3) 463 (52.1) 261 (54.0) 0.229 
Body mass index, 
kg/m2, mean (SD) 26.0 (4.7) 25.8 (4.5) 26.1 (4.6) 26.1 (4.8) 26.2 (4.9) 25.6 (4.7) 0.090 
No comorbidity 2083 (46.0) 516 (45.4) 468 (46.0) 466 (46.6) 414 (46.6) 219 (45.3) 0.974 
Heart disease 597 (13.2) 163 (14.3) 124 (12.2) 144 (14.4) 103 (11.6) 63 (13.0) 0.243 
Diabetes mellitus 414 (9.1) 100 (8.8) 101 (9.9) 92 (9.2) 83 (9.3) 38 (7.9) 0.755 
Prior Stroke/TIA 232 (5.1) 48 (4.2) 59 (5.8) 50 (5.0) 45 (5.1) 30 (6.2) 0.397 
Chronic kidney 
disease 83 (1.8) 22 (1.9) 21 (2.1) 17 (1.7) 12 (1.3) 11 (2.3) 0.708 
Performance 
status 1 or 2* 1820 (40.2) 435 (38.3) 427 (41.9) 428 (42.8) 362 (40.7) 168 (34.8) 0.019 
Current smoker 1311 (29.0) 325 (28.6) 285 (28.0) 281 (28.1) 274 (30.8) 146 (30.2) 0.593 
Preoperative 
chemotherapy 125 (2.9) 31 (2.8) 30 (3.0) 28 (2.9) 28 (3.2) 8 (1.7) 0.581 
Preoperative 
radiotherapy 195 (4.5) 43 (3.9) 35 (3.6) 55 (5.8) 50 (5.8) 12 (2.5) 0.007 
Preoperative PET 3639 (87.3) 910 (87.2) 823 (87.6) 805 (88.7) 714 (86.9) 387 (85.2) 0.485 
Lobectomy or 
more 3467 (76.6) 882 (77.6) 761 (74.8) 779 (77.8) 685 (77.1) 360 (74.5) 0.329 
VATS 682 (15.1) 182 (16.0) 145 (14.2) 144 (14.4) 119 (13.4) 92 (19.0) 0.047 
Stage IIIA or 
above** 872 (19.3) 230 (20.2) 193 (19.0) 177 (17.7) 174 (19.6) 98 (20.3) 0.603 
Extended surgery 186 (4.1) 36 (3.2) 42 (4.1) 48 (4.8) 46 (5.2) 14 (2.9) 0.087 
No microscopic 
radicality 681 (15.0) 152 (13.4) 173 (17.0) 146 (14.6) 126 (14.2) 84 (17.4) 0.081 
Data are represented as n (%) unless otherwise noted. SD = standard deviation. TIA = transient ischemic 
attack. PET = positron emission tomography. VATS = video-assisted thoracic surgery. 
An extended surgery involved any structure other than the lung or lymph nodes that was included in the 
resection (e.g. thoracic wall, diaphragm, pericardium). 
*Compared with performance status 0, there was no patient with performance status 3 or 4. 
**Pathological stage 
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Table 13. Survival 
Kaplan–Meier estimated survival and difference in RMST(days) according to the weekday of 
surgery 1- and 5-years postoperatively of patients who underwent pulmonary resection for lung 
cancer (n = 4528). 
 
K–M estimated survival 
(95% CI) 
Restricted mean 
survival time, 
days (95% CI) 
Difference in survival time 
vs Monday, days (95% CI) 
p value 
1-Year follow-up 
Monday 88% (86-90) 344 (340-348) - - 
Tuesday 90% (88-92) 349 (345-352) 4.4 (-1.1-9.8) 0.119 
Wednesday 89% (87-91) 347 (343-351) 2.5 (-3.1-8.1) 0.381 
Thursday 89% (87-91) 346 (342-351) 2.1 (-3.8-7.9) 0.489 
Friday 90% (87-92) 346 (340-352) 1.6 (-5.7-8.9) 0.664 
5-year follow-up 
Monday 61% (58-64) 1408 (1371-1446) - - 
Tuesday 60% (56-63) 1414 (1376-1452) 6.0 (-47-59) 0.826 
Wednesday 58% (55-62) 1383 (1344-1423) -15 (-79-29) 0.368 
Thursday 60% (56-64) 1391 (1349-1433) -17 (-73-39) 0.547 
Friday 59% (53-64) 1405 (1349-1461) -3.5 (-71-65) 0.919 
CI = confidence interval, K–M = Kaplan–Meier analysis, RMST = restricted mean survival time. 
 
  
Table 12. Event rates and risks of all-cause mortality. 
Event rates and relative risks for all-cause mortality after pulmonary resections for patients with 
lung cancer in Sweden from 2009 to 2015 associated with the weekday of surgery. 
 
Number of 
deaths/Person-
Years 
Unadjusted 
mortality rate per 
100 Person-Years 
(95% CI) 
Crude 
HR (95% CI) 
Multivariable* 
adjusted 
HR (95% CI) 
Monday 387/3738 10 (9.4-11) Ref. Ref. 
Tuesday 355/3452 10 (9.3-11) 0.99 (0.86-1.15) 0.98 (0.85-1.13) 
Wednesday 369/3317 11 (10-12) 1.08 (0.93-1.24) 1.03 (0.89-1.19) 
Thursday 317/2946 11 (9.6-12)  1.04 (0.90-1.21) 0.99 (0.85-1.15) 
Friday 170/1513 11 (9.7-13) 1.07 (0.89-1.28) 1.04 (0.87-1.25) 
*Model includes all variables reported in Table 1. 
Ref. = reference category, HR = hazard ratio, CI = confidence interval. 
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Figure 13. Kaplan–Meier analysis of estimated overall survival of 4528 patients who 
underwent pulmonary resection for lung cancer in Sweden from 2009 to 2015 
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6 DISCUSSION 
6.1 STUDY I 
Study I demonstrates an independent and statistically significant association between 
preoperative self-reported HRQOL and survival after a median follow-up of 8 years 
among patients who underwent lung surgery at Karolinska University Hospital. The 
preoperative physical component of QOL lower than the reference values was 
associated with poor long-term survival, independent of several patient-related 
factors, of which the most important were age, histopathological findings, cancer 
stage, and extent of surgery. Study I used the validated SF-36 questionnaire, taking 
advantage of its availability in different languages and the opportunity to compare 
the results with the reference scores of the general population. A recent survey 
among members of the ESTS shows that approximately 50% of ESTS centers 
routinely collect HRQOL questionnaires and the widely used SF-36 questionnaire.65 
In Study I, the association between low PCS scores and subgroups stratified according 
to tumor stage did not show a statistically significant increase in mortality associated 
with stage 0 and stages II to III, likely explained by the small number of patients and 
events (death) in these subgroups. However, the point-estimates suggest a relation 
between physical QOL and mortality that is similar to our main findings for the total 
study population. 
Möller and Sartipy investigated the association between self-reported HRQOL of 
thoracic surgery and clinical postoperative outcomes using the SF-36 questionnaire 
submitted to patients scheduled for thoracic surgery at Karolinska University Hospital 
between 2006 and 2008.10, 18 They found that changes in the self-reported QOL, 
postoperative six months, and a 10% decline in the PCS and MCS scores are 
associated with 18% and 13% increases in postoperative mortality, respectively.10 
Further, there is an association between HRQOL, sex months after thoracic surgery, 
and long-term survival, which is independent of preoperative, baseline life quality 
scores.10, 18 In Study I, the same population of 249 patients who completed the 
preoperative questionnaire were included and long-term survival was explored. The 
median follow-up was 8 years compared with the 4-year median follow-up time of 
the previous studies.  
HRQOL is a subjective measure reflecting the effects of disease or treatment on a 
patient’s physical and mental status. Thus, objective functional measures cannot 
replace or encompass these aspects of the health assessment. It is reasonable to 
conclude that HRQOL scores may reflect good general health and its consequences, 
which may affect health-consciousness, diet, physical activity, and sufficient 
compliance with medical therapy to improve prognosis.8 
The association between HRQOL and survival after lung surgery is the subject of 
several reports. For example, Pompili et al. investigated preoperative predictions of 
survival based on the physical HRQOL of patients with early-stage lung cancer who 
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underwent lobectomy.17 In Study I, the wide inclusion criteria used to select patients 
and procedures confers the advantage of generalization to clinical practice. Patients 
with benign and malignant diseases at various stages and different types of lung 
resections are included in the study. 
Study I tested only the SF-36 instrument and speculates that the results from other 
HRQOL instruments may be similar. However, this hypothesis should be verified by 
specific studies before firm conclusions can be drawn. 
The prediction by Study I of long-term mortality can serve as an important 
complement to the current risk prediction tool such as the Thoracoscore, which was 
developed for estimating mortality during hospitalization and subsequently for 
midterm mortality after thoracic surgery.66 Accordingly, Study I strongly recommends 
the inclusion of self-reported HRQOL for the future development of risk-prediction 
models of long-term survival after thoracic procedures. 
6.2 STUDY II 
Study II revealed a remarkable increase in the number of pulmonary metastasectomy 
procedures for treating CRC at Karolinska University Hospital between 2004 and 
2015, which achieved 60% 5-year survival. Prethoracotomy CEA concentrations >4 
ng/mL was the only significant prognostic factor associated with poor long-term 
survival. 
Recent advances in the management of CRC have significantly improved survival, 
including patients with metastatic disease.23 The 5-year survival rate of metastatic 
CRC increased from 25% to 50%.67 During the mid-1990s, surgical resection of liver 
metastases from CRC was adopted and gradually accepted in clinical practice as a 
component of multidisciplinary management to improve survival, despite the lack of 
strong evidence to support its influence on improving survival.24 Similarly, pulmonary 
metastasectomy of CRC became widely accepted, which depended on growing 
evidence contributed only by retrospective observational studies.25 Despite the large 
number of nonrandomized studies and meta-analyses, the need for a randomized 
study is increasing to recognize whether the survival benefit conferred upon these 
patients is attributable to surgical intervention, bias in patient selection, lead-time, or 
staging migration.68 The PulMiCC is a randomized controlled trial currently recruiting 
patients from the United Kingdom and Europe, which is designed to answer clinical 
questions about the feasibility of pulmonary metastasectomy for CRC to improve 
survival and to inform and guide clinical practice.33 
The incidence of CRC in Europe and the United States is decreasing, and the criteria 
for patient selection for surgery did not change during Study II and therefore cannot 
explain the continuous increase in the number of procedures.69 Presumably, recent 
developments in the diagnosis, surgical techniques, and therapy of CRC contribute to 
the increased frequency of early discovery of resectable metastases and encourage 
oncologists and surgeons to employ more aggressive strategies such as surgical 
resection to manage metastatic CRC.22, 23 
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The long-term survival reported by the present study is comparable with, if not better 
than overall survival data reported by others. For example, Gonzalez et al. conducted 
a meta-analysis that revealed that overall 5-year survival rates ranges from 27% to 
68%,27 and another contemporaneous study found that disease-specific 5-year 
survival is 46.1% (95% CI, 38.5% to 53.7%).28 These wide differences reflect the 
differences in the criteria used to select patients for surgery. Moreover, 5-year 
survival may be higher if patients who are accepted for surgery have a long DFI, 
solitary metastases, no lymph nodes metastases detected using PET-CT, and low 
prethoracotomy CEA concentrations. In our institution, all patients are accepted after 
they are discussed at multidisciplinary team conferences, and we follow the clinical 
practice guidelines and the team’s recommendations.21, 70 Criteria that justify PM-CRC 
are as follows: radically treated primary tumor; absence of extrathoracic metastases, 
or if present, radically treated or amenable to radical treatment; resectable 
pulmonary metastases; and good general condition consistent with a safe surgical 
outcome. 
Prethoracotomy CEA levels are thoroughly investigated in the literature, and Study II 
as well as those of others found a consistently significant association between high 
concentrations of CEA and worse prognosis of survival.27-29 The cut-off for normal vs 
elevated CEA concentrations in Study II was 4 ng/mL, and 51% of patients had CEA 
concentrations <4 ng/mL. In contrast, other studies defined a cut-off level ≤5 ng/mL. 
Further, Embun et al. conducted a multicenter, prospective cohort study showing that 
69% of patients have prethoracotomy CEA concentrations ≤5 ng/mL, and 35% 
experience DFI >24 months.28 Similarly, Gonzalez et al. conducted a meta-analysis of 
2,925 patients from 25 studies that demonstrated a pooled outcome with a 
significantly increased risk of mortality associated with high concentrations of 
prethoracotomy CEA.27 Similar to Study II, a retrospective study of 94 patients 
performed by Suzuki et al. found that the prethoracotomy CEA concentration was the 
only statistically significant prognostic factor of long-term survival, with 5-year 
survival rates of 57% and 30.9% for patients with normal or high CEA concentrations, 
respectively (p = 0.038).29 
As a prognostic factor, prethoracotomy CEA concentrations have conflicting 
consequences for clinical applications, because high CEA concentrations may lead to 
further investigations with imaging and early diagnosis of pulmonary metastases 
suitable for surgical resection.71 In contrast, high CEA concentrations predict poor 
survival and may lead physicians not to offer surgery.71 We believe that 
prethoracotomy CEA concentrations associated with pulmonary metastasectomy can 
be used to help detect recurrent disease early during follow-up and consequently may 
enable rapid intervention. 
DFI is considered by many studies as a prognostic factor for survival, although the 
results conflict and gave conflicting results. For example, Gonzalez et al. and Embun 
et al. found that short DFI predicts worse survival,27, 28 although several other studies 
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do not demonstrate this association.29, 30, 72 In Study II, 48% of patients with DFI >24 
months is not significantly associated with survival. 
6.3 STUDY III 
Study III, which is a nationwide study conducted in Sweden, found that 5-year 
survival after PM-CRC is 56%, which is higher compared with the findings of previous 
report,27 reflected appropriate selection criteria of patients scheduled for surgery. In 
Study III, external validation of a recently proposed Japanese prognostic model for 
survival after PM-CRC, achieved good discrimination among Swedish patients. Thus, 
low-risk patients achieved statistically significant longer survival compared with the 
moderate- or high-risk groups, despite the lack of determination of prethoracotomy 
CEA concentrations. Similar to Study II, the number of surgeries performed between 
2009 and 2015 increased, and Figure 7 reveals incomplete reporting to the ThoR 
register before 2013. 
Several prognostic factors were identified in numerous nonrandomized studies that 
focused on how to facilitate and optimize patient selection for surgery and to predict 
long-term outcomes after surgery. These prognostic factors include the following: 
prethoracotomy CEA concentrations,27-29, 31 DFI,27, 28, 31 number of pulmonary 
metastases,27, 31 and involvement of thoracic lymph nodes.27, 28, 73 Few of these studies 
attempted to construct multivariable risk prediction models by combining these and 
other factors to improve their discriminatory capacity compared with the use of single 
prognostic factors.28, 31, 74 However, to the best of our knowledge, none of these 
models was externally validated or is widely used in clinical applications. 
Okumura et al., who recently suggested a practical and well-designed risk prediction 
model for patients scheduled to undergo PM-CRC, assigned five preoperative risk 
factors to construct three risk categories depending on the number of risk factors.31 
The study includes data for 785 Japanese patients treated at 46 hospitals in Japan 
who underwent surgery between 2004 and 2008. The lack of prethoracotomy CEA 
concentrations in Study III represents a significant limitation to external validation of 
the proposed prediction model, because some patients were incorrectly classified in 
the low- and moderate-risk categories instead of moderate- and high-risk groups. 
Further, external validation of a risk model usually assesses discrimination and 
calibration. However, in our validation, we were obliged to employ only 
discrimination because of the lack of prethoracotomy CEA concentrations as well as 
missing DFI data for 25% of patients. However, the study showed an excellent ability 
to discriminate among Swedish patients with statistically significant higher mortality 
of moderate- and high-risk patients compared with low-risk patients. We believe that 
this promising risk-prediction model can assist patient selection for surgery in a way 
that will be practical and easy for surgeons and patients. 
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6.4 STUDY IV 
To our knowledge, the first and only report on VATS lobectomy in Sweden, published 
in 1998, investigated 30 patients who underwent VATS lobectomy with simultaneous 
stapling technique.75 The VATS lobectomy program started at Karolinska University 
Hospital in 2012 as an alternative to thoracotomy for treating lung tumors. After a 
few years, VATS lobectomy became the standard approach for resection of patients 
with early-stage NSCLC. The program was conducted by three dedicated surgeons 
specializing in GTS, following the well-organized Copenhagen model.40 The same 
protocol was used for all VATS lobectomy procedures, which includes the 
standardized three-port anterior approach, the same surgical instruments, and video-
thoracoscope. These factors, together with a sufficient number of surgeries per 
surgeon, are important for maintaining the success and rapid progress of the 
program. For example, McElnay et al. found a remarkable increase in the rate of 
VATS lobectomies after the adoption of the Copenhagen program and approach.41 
Study IV compared patients who underwent VATS lobectomy for early stage NSCLC 
at Karolinska University Hospital with patients who underwent thoracotomy at other 
hospitals in Sweden. Study IV excluded patients who underwent thoracotomy–
lobectomy at our institution, because they were considered unsuitable for VATS 
lobectomy at the time of the decision to offer surgery, or some patients were 
converted from VATS. Further, the few patients (n = 14) who underwent VATS 
lobectomy at hospitals other than the Karolinska were excluded to facilitate acquiring 
the data and arriving at conclusions of their significance. The difference in patients’ 
baseline characteristics evaluated using IPTW, which was based on a propensity 
score, achieved an excellent balance between the groups. Thus, the standardized 
mean differences among all variables after weighting was <0.1. However, the results 
of Study IV should be carefully evaluated because of the probability of undetected 
differences between the groups. 
More than 80% of patients in both groups did not experience peri- or postoperative 
complications; however, the VATS group was associated with fewer blood 
transfusions, a high proportion of drain removal on the first postoperative day, and 
less postoperative pneumonia, consistent with the findings of numerous reports.76-80 
We were unable to reach a definitive conclusion about the superiority of the VATS 
technique vs the thoracotomy approach in Study IV due to the low rate of 
complications in both groups. These results support our expectations of the feasibility 
and safety of VATS lobectomy for treating patients with NSCLC. 
Although the duration of hospitalization of patients in the VATS group was shorter 
compared with those of the thoracotomy group, more patients in the VATS group 
were referred to rehabilitation. This may reflect the differences in practice and policy 
among institutions in Sweden and not the approach. In a double-blind randomized 
controlled trail, patients who underwent VATS lobectomy experienced less 
postoperative pain and better HRQOL compared with patients who underwent 
anterolateral thoracotomy.36 
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Data acquired by nonrandomized observational studies of long-term survival after 
VATS lobectomy compared with those for thoracotomy, vary from no differences to 
better survival achieved by the former approach. For example, a study conducted in 
the United States by Yang et al. demonstrates shorter hospitalization and noninferior 
long-term survival after VATS lobectomy compared with thoracotomy.44 Similarly, 
Paul et al. showed that VATS lobectomy is associated with equivalent overall survival, 
cancer-specific and disease-free survival compared with open thoracotomy.81 The 
study cited, which employs propensity-score matching of >6000 patients with 
primary NSCLC, identified 1195 patients in each group after matching.81 In Study IV, 
the VATS group experienced longer long-term survival as follows: overall 1- and 5-
year survival rates were 92% vs 97% and 63% vs 78% in the open thoracotomy and 
VATS groups, respectively (HR [95% CI], 0.47 [0.33–0.68], p<0.001). These results 
are consistent, before and after weighting of the covariates. Moreover, when the 
analysis of patients restricted to those with cancer stages I and IIA was repeated, we 
obtained the same statistically significant results (HR [95% CI], 0.59 (0.39–0.88), p 
= 0.009). Further, a single-center study conducted in Poland by Dziedzic et al. 
demonstrates better survival after VATS lobectomy compared with thoracotomy.82 It 
is important to note the aim of Study IV was to investigate the feasibility and safety of 
VATS lobectomy for treating patients with early-stage NSCLC, but not to evaluate the 
direct effects of treatment. Consequently, the results of Study IV, particularly long-
term survival, must be interpreted with caution before application to the clinic. 
6.5 STUDY V 
Study V did not detect a difference in survival outcomes among patients who 
underwent pulmonary resections for lung cancer on different days of the week. Fewer 
surgeries were performed on Fridays, and the patients and surgical techniques were 
comparable among all groups. The HR was not statistically significant for all-cause 
mortality in crude or adjusted analysis. Using Monday as a reference, we consider the 
difference in RMST clinically negligible at the 1- and 5-year follow-up examinations 
(1.6 days to 4.4 days and –17 days to 6 days, respectively). In the Swedish healthcare 
system, in-theater time is approximately 50% shorter on Fridays, which explains the 
decreased number of operations compared with other weekdays. The annual risk of 
death is approximately 10%, independent of the weekday of surgery. 
The results of numerous studies on the effects of the weekday of surgery on short- 
and long-term survival among diverse surgical disciplines are inconsistent. For 
example, a nationwide cohort study conducted in Sweden of 106 473 patients who 
underwent cardiac surgery found no evidence of an association of the weekday of 
surgery on survival, which is consistent with the conclusions of Study V.63 Another 
study found that surgery performed later in the week is associated with poor survival 
of patients with gastrointestinal cancer (e.g. esophagogastric cancer) (HR, 1.57; CI 
95%, 1.31–1.88), liver/pancreatic/biliary cancer (HR, 1.49; CI 95%, 1.17–1.88), and 
CRC, (HR, 1.53; CI 95%, 1.44–1.63), but not for other common cancers such as lung 
cancer. In patients with lung cancer (n = 2537), the crude and adjusted HRs for 
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disease-specific mortality for Fridays and Mondays are 0.09 (CI 95%, 0.87_1.37) and 
1.04 (CI 95%, 0.82–1.31), respectively.83 These findings strongly support the results 
of Study V, because they were published by different investigators who studied 
cohorts of patients from the same country. 
The differences in clinical practice and healthcare systems among clinics and 
countries makes the comparison between results of studies in this context difficult 
and complex. For example, a study conducted by Singla et al. found that 7718 
patients undergoing surgery on a weekend vs a weekday experienced poor short-term 
survival. In this cohort, >80% underwent emergency and general surgery that 
contributed to approximately 40% of early mortality, whereas early mortality after 
cardiothoracic surgery was 8%. Further, patients who underwent elective 
cardiothoracic surgery experienced higher early postoperative mortality. These results 
reflect the inherent high risk of elective cardiothoracic procedures,59 however, Dalén 
et al. as well as Study V did not identify a significant association between the 
weekday of surgery and mortality of patients who underwent cardiothoracic 
surgery.63 A retrospective analysis of the national hospital administrative data of 
English public hospitals evaluated 4 133 346 patients who underwent elective 
surgery.57 This study found that 15927 patients who underwent elective lung 
resections experienced a significant increase in short-term mortality when surgery 
was conducted on Fridays and weekends compared with Mondays.57 The results of 
Study V are inconsistent with these results, but interpretation must take into account 
the difference in the study populations. Study V only included patients with lung 
cancer, and the study cited57 included all patients who underwent lung excision. 
Moreover, the authors reported significant limitations of their study that included the 
inability to adjust for inherent selection bias and acknowledged that the adjustment 
for risk associated with the procedure was not based on clinical severity. In Study V, 
the ThoR register, with its clinical details and complete reporting since 2013, 
effectively minimized selection bias. 
6.6 LIMITATIONS 
6.6.1 Study I 
Study I specifically tested the SF-36 tool and its generalizability. Other instruments of 
HRQOL measures require separate, meticulous studies to test their abilities to predict 
survival. Data were missing for smoking history (8%) and forced expiratory volume in 
1 second (15%). The missing data might have skewed the results; however, the 
amount of missing data for these variables was not large, and the data were managed 
using multiple imputation and chained equations.  
6.6.2 Study II 
The study size (n = 184) was insufficient to recognize small differences between 
groups; however, the number of patients was acceptable and larger compared with 
the sizes of numerous other contemporaneous studies on same subject with similar 
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study designs.27 Missing prethoracotomy CEA concentrations (40%) represents 
another limitation, which may confer the probable disadvantage of misrepresenting 
the results. Nonetheless, the prethoracotomy CEA concentration was the only 
statistically significant prognostic factor, which is consistent with the results of other 
reports. Therefore, we believe that complete data for this variable will provide 
stronger supporting evidence. Other limitations include unknown confounders and 
bias inherent in all retrospective studies, despite implementation of meticulous 
statistical measures. 
6.6.3 Study III 
The lack of prethoracotomy CEA concentrations in Study III was a significant 
limitation, because this variable is not included in the ThoR register. Consequently, 
certain patients were incorrectly classified into the low- or moderate-risk categories 
instead of the moderate- or high-risk categories. Another limitation, caused in part by 
the lack of CEA concentrations, was the restriction of the external validation of the 
risk model to only discrimination assessment without calibration. Another limitation 
was that DFI was missing in some patients. 
6.6.4 Study IV 
Study IV was limited by its lack of information from the ThoR register on the 
conversion rate of VATS to thoracotomy, leading to the exclusion of these patients 
from the study, which exaggerated the expectation of the superiority of VATS 
compared with thoracotomy. Other limitations were the lack of lymph-node sampling 
or clearance and the inability to compare tumor upstaging between the two groups as 
reported in the literature.84 
6.6.5 Study V 
This nationwide study was conducted within the Swedish healthcare system, which 
limits the generalization of the findings to thoracic centers in other countries. 
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7 CONCLUSIONS 
7.1 STUDY I 
Preoperative physical QOL lower than the reference value was significantly associated 
with worse survival of patients who underwent thoracic surgery. This association was 
independent of histopathology, cancer stage, extent of surgery, and other patient-
related factors. The mental component of the HRQOL was not significantly associated 
with long-term survival. The study recommends inclusion of physical QOL in future 
risk models designed to predict long-term survival after thoracic surgery. 
7.2 STUDY II 
The overall 5-year survival after patients with CRC underwent pulmonary 
metastasectomy was 60%, which is consistent with the longest overall survival rates 
previously reported. The number of surgeries increased during the study period. High 
prethoracotomy CEA level ≥4 ng/mL was the only prognostic factor identified with 
significant association with poor postoperative long-term survival. 
7.3 STUDY III 
The overall 5-year survival rate after patients with CRC underwent pulmonary 
metastasectomy in Sweden (56%) is among the longest compared with the results of 
contemporaneous reports, suggesting appropriate patient selection criteria. We also 
showed that a prognostic model, initially developed in Japanese cohort of patients, 
successfully provided risk stratification in an external validation cohort of Swedish 
patients. 
7.4 STUDY IV 
VATS lobectomy of patients with early-stage NSCLC was associated with fewer 
postoperative complications, improved clinical short-term outcomes, and increased 
long-term survival compared with thoracotomy. VATS lobectomy was feasible and 
safe for treating patients with early-stage NSCLC. 
7.5 STUDY V 
The weekday of surgery was not significantly associated with long-term survival of 
patients who underwent surgical treatment for lung cancer in Sweden. The results do 
not support implementing changes in staffing policies or rescheduling of surgery. 
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